IP Library › Granted Patent US 9,149,219
Granted Patent B2
US 9,149,219 · App. 13/024,076 · Granted Oct 6, 2015

Systems and methods for replacing signal artifacts in a glucose sensor data stream

Inventors: Paul V. Goode, Jr. (Cherry Hill, NJ); James H. Brauker (Addison, MI); Apurv U. Kamath (San Diego, CA); James Patrick Thrower (Oakland, NJ); Victoria Carr-Brendel (San Diego, CA)
Assignee: DexCom, Inc.
A61B5/14865A61B5/0031A61B5/14532A61B5/14539A61B5/7203A61B5/726A61B5/7225
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,149,219
App. No.
13/024,076
Granted
Oct 6, 2015
Kind
B2
Abstract

Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.

Claims (39)

1. A computer-implemented method for administering a medicament therapy to a host, comprising:

monitoring a data stream from a glucose sensor, the data stream indicative of a glucose concentration of a host;

calibrating the data stream;

detecting transient non-glucose related signal artifacts and evaluating a severity thereof;

replacing with an electronic device at least some of the signal artifacts with one or more physiologically feasible estimated glucose values in response to the evaluated severity, wherein replacing at least some of the signal artifacts comprises estimating a glucose concentration value, wherein estimating utilizes physiological information along with the data stream in order determine the one or more physiologically feasible estimated glucose values; and

controlling administration of a medicament to the host, using a medicament delivery device, based on the one or more physiologically feasible estimated glucose values.

2. The method of claim 1 , wherein replacing at least some of the signal artifacts with one or more estimated glucose values further comprises outputting data representative of the one or more estimated glucose values, including outputting by at least one of a numeric representation of the one or more estimated glucose values, an indication of directional trend of the one or more estimated glucose values, or a graphical representation of the one or more estimated glucose values.

3. The method of claim 2 , further comprising filtering the data stream, wherein the one or more estimated glucose values are based on the filtered data stream.

4. The method of claim 1 , wherein monitoring a data stream comprises receiving data from at least one of a non-invasive glucose sensor, a minimally invasive glucose sensor, or an invasive glucose sensor.

5. The method of claim 1 , wherein monitoring a data stream comprises receiving data from at least one of an enzymatic glucose sensor, a chemical glucose sensor, a physical glucose sensor, an electrochemical glucose sensor, a spectrophotometric glucose sensor, a polarimetric glucose sensor, a calorimetric glucose sensor, an iontophoretic glucose sensor, or a radiometric glucose sensor.

6. The method of claim 1 , wherein replacing at least some of the signal artifacts is substantially continual.

7. The method of claim 1 , wherein replacing at least some of the signal artifacts is initiated when the severity of signal artifacts meets a criterion.

8. The method of claim 1 wherein replacing at least some of the signal artifacts is terminated when the severity of signal artifacts meets a criterion.

9. The method of claim 1 , further comprising discarding at least some of the signal artifacts.

10. The method of claim 1 , wherein detecting transient non-glucose related signal artifacts in the data stream is performed on the calibrated data stream.

11. The method of claim 1 , wherein replacing at least some of the signal artifacts with one or more estimated glucose values comprises outputting or displaying the one or more estimated glucose values.

12. The method of claim 1 , further comprising filtering the monitored data stream.

13. The method of claim 1 , wherein the data stream comprises a filtered data stream.

14. The method of claim 1 , wherein the data stream comprises a raw data stream.

15. The method of claim 1 , further comprising outputting the one or more estimated glucose values.

16. The method of claim 1 , further comprising outputting the data stream.

17. The method of claim 1 , further comprising evaluating whether the one or more estimated glucose values is outside a predetermined range, wherein the predetermined range is defined by boundaries derived from a projected rate of change and/or acceleration of estimated glucose values.

18. The method of claim 1 , further comprising storing the one or more estimated glucose values.

19. The method of claim 1 , further comprising displaying the one or more estimated glucose values.

20. The method of claim 1 , wherein the medicament is insulin.

21. A medicament delivery system for administering a therapy to a host, comprising one or more processors and computer code that, when executed by the one or more processors, cause the delivery system to:

monitor a data stream from a glucose sensor, the data stream indicative of a glucose concentration of a host;

calibrate the data stream;

detect transient non-glucose related signal artifacts and evaluating a severity thereof;

replace at least some of the signal artifacts with one or more physiologically feasible estimated glucose values in response to the evaluated severity, wherein replacing at least some of the signal artifacts comprises estimating a glucose concentration value, wherein estimating utilizes physiological information along with the data stream in order determine the one or more physiologically feasible estimated glucose values; and

control administration of a medicament to the host, using a medicament delivery device, based on the one or more physiologically feasible estimated glucose values.

22. The system of claim 21 , wherein replacing at least some of the signal artifacts is substantially continual.

23. The system of claim 21 , wherein replacing at least some of the signal artifacts is initiated when the severity of signal artifacts meets a criterion.

24. The system of claim 21 , wherein replacing at least some of the signal artifacts is terminated when the severity of signal artifacts meets a criterion.

25. The system of claim 21 , wherein detecting transient non-glucose related signal artifacts in the data stream is performed on the calibrated data stream.

26. The system of claim 21 , wherein replacing at least some of the signal artifacts with one or more estimated glucose values comprises outputting or displaying the one or more estimated glucose values.

27. The system of claim 21 , wherein the software code, when executed by the one or more processors, further causes the delivery system to display the one or more estimated glucose values on a display screen of the system.

28. The system of claim 21 , wherein the software code, when executed by the one or more processors, further causes the delivery system evaluate whether the one or more estimated glucose values is outside a predetermined range, wherein the predetermined range is defined by boundaries derived from a projected rate of change and/or acceleration of estimated glucose values.

29. The system of claim 21 , wherein the medicament is insulin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2014
From: GOODE, PAUL V., JR.; BRAUKER, JAMES H.; KAMATH, APURV U.; THROWER, JAMES PATRICK; CARR-BRENDEL, VICTORIA
To: DEXCOM, INC.
Reel/Frame 032890/0098 →
Continuity (2)
Continuation 10648849 · Aug 22, 2003
Related Publication 20110130998A1 · Jun 2, 2011